

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Living with Dementia in Aotearoa (LiDiA): a feasibility study protocol for a dementia prevalence study in Aotearoa / New Zealand.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046143
Article Type:	Protocol
Date Submitted by the Author:	26-Oct-2020
Complete List of Authors:	<p>Martinez-Ruiz, Adrian; The University of Auckland, Department of Psychological Medicine; National Institute of Geriatrics, Department of Demographic Epidemiology and Social Determinants</p> <p>Yates, Susan; The University of Auckland, Department of Psychological Medicine</p> <p>Cheung, Gary ; The University of Auckland, Department of Psychological Medicine</p> <p>Dudley, Makarena; The University of Auckland, School of Psychology</p> <p>Krishnamurthi, Rita; Auckland University of Technology, National Institute for Stroke and Applied Neurosciences</p> <p>Fa'alau, Fuafiva ; The University of Auckland, School of Population Health</p> <p>Roberts, Mary; Moana Research, Research Department</p> <p>Taufa, Seini ; Moana Research, Research Department</p> <p>Fa'alili-Fidow, Jacinta; Moana Research, Research Department</p> <p>Rivera-Rodriguez, Claudia; The University of Auckland, Department of Statistics</p> <p>Kautoke, Staverton ; Counties Manukau District Health Board, Department of Mental Health Services for Older People</p> <p>Ma'u, Etuini ; The University of Auckland, Department of Psychological Medicine</p> <p>Kerse, Ngaire; The University of Auckland, School of Population Health</p> <p>Cullum, Sarah; The University of Auckland, Department of Psychological Medicine</p>
Keywords:	Dementia < NEUROLOGY, Old age psychiatry < PSYCHIATRY, GERIATRIC MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Living with Dementia in Aotearoa (LiDiA): a feasibility study protocol for a dementia**  
4 **prevalence study in Aotearoa / New Zealand.**  
5  
6  
7  
8  
9

10 **Adrian Martinez-Ruiz**<sup>1,2</sup>, MD, Susan Yates<sup>1</sup> PhD, Gary Cheung<sup>1</sup> PhD, Makarena Dudley<sup>3</sup>  
11 PhD, Rita Krishnamurthi<sup>4</sup> PhD, Fuafiva Fa'alau<sup>5</sup> PhD, Mary Roberts<sup>6</sup> MNsg, Seini Taufu<sup>6</sup> PhD,  
12 Jacinta Fa'alili-Fidow<sup>6</sup> PhD, Claudia Rivera Rodriguez PhD<sup>7</sup>, Staverton Kautoke<sup>8</sup> MBChB,  
13 Etuini Ma'u<sup>1</sup> MBChB, Ngaire Kerse<sup>5</sup> PhD, Sarah Cullum<sup>1</sup> MBChB PhD.  
14  
15  
16  
17  
18  
19  
20  
21  
22

- 23 (1) Department of Psychological Medicine, The University of Auckland, Auckland, New  
24 Zealand.  
25  
26  
27 (2) Department of Demographic Epidemiology and Social Determinants, National Institute of  
28 Geriatrics, Mexico City, Mexico.  
29  
30 (3) School of Psychology, The University of Auckland, Auckland, New Zealand.  
31  
32 (4) National Institute for Stroke and Applied Neurosciences, Auckland University of  
33 Technology, Auckland, New Zealand.  
34  
35 (5) School of Population Health, The University of Auckland, Auckland, New Zealand.  
36  
37 (6) Research Department, Moana Research, Auckland, New Zealand.  
38  
39 (7) Department of Statistics, The University of Auckland, Auckland, New Zealand.  
40  
41 (8) Department of Mental Health Services for Older People, Counties Manukau District Health  
42 Board, Auckland, New Zealand.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Correspondence to Dr Adrian Martinez-Ruiz; a.martinez@auckland.ac.nz  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Aotearoa New Zealand (NZ) is officially recognized as a bicultural country comprised of Māori and non-Māori. Recent estimations have projected a threefold increase in dementia prevalence in NZ by 2050, with the greatest increase in non-NZ Europeans. The NZ government will need to develop policies and plan services to meet the demands of the rapid rise in dementia cases. However, to date there is no national data on dementia prevalence and overseas data are used to estimate the NZ dementia statistics. The overall aim of the Living with Dementia in Aotearoa (LiDiA) study is to prepare the groundwork for a large full-scale NZ dementia prevalence study.

**Methods and analysis:** The study has two phases. In phase one, we will adapt and translate the 10/66 dementia assessment protocol to be administered in Māori, Samoan, Tongan and Fijian-Indian elders. The diagnostic accuracy of the adapted 10/66 protocol will be tested in older people from these ethnic backgrounds who were assessed for dementia at a local memory service. In phase two, we will address the feasibility issues of conducting a population-based prevalence study, by applying the adapted 10/66 protocol in South Auckland and will include NZ European, Māori, Samoan, Tongan, Chinese, and Fijian-Indian participants. The feasibility issues to be explored are: (i) How do we sample to ensure we get accurate community representation? (ii) How do we prepare a workforce to conduct the fieldwork and develop quality control? (iii) How do we raise awareness of the study in the community to maximize recruitment? (iv) How do we conduct door-knocking to maximize recruitment? (v) How do we retain those we have recruited to remain in the study? (vi) What is the acceptability of study recruitment and the 10/66 assessment process in different ethnic groups?

## Ethics and dissemination

The validity and feasibility studies were approved by the New Zealand Northern A Health and Disability Ethics Committee, Number: 17NTA234 and 18NTA176 respectively. The findings will be disseminated through peer-reviewed academic journals, national and international conferences and public events. Data will be available upon reasonable request to the corresponding author.

1  
2  
3 ***Strengths and limitations of this study***  
4  
5

- 6
- 7 • The results of the validity and feasibility studies will prepare the groundwork for the  
8 first population-based dementia prevalence study in New Zealand.  
9
  - 10 • The validity study will result in an internationally recognised dementia diagnostic tool  
11 to be used in research with Māori, Fijian-Indian, Samoan and Tongan elders living in  
12 New Zealand.  
13
  - 14 • Due to time and funding constraints not all ethnic minorities in New Zealand will be  
15 included in this phase of the study.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ***Introduction***

Dementia is a global health priority and its prevalence is increasing in many parts of the world due to their ageing populations (1). Governments across the world are developing policies and planning services to meet the health care and social needs of people with dementia. Aotearoa New Zealand (NZ) needs to do the same but to date there is no prevalence data at a national level to inform the extent and impact of dementia on our population. Although it has been projected that over 60,000 people are currently living with dementia in NZ (at a cost of \$1700 million per annum) and it will increase to 170,000 people by 2050 (2), these statistics are extrapolated from other countries data.

Globally, the prevalence of dementia in people aged 60 years and over is reported to be between 5.6% to 7.6% (3). However, the prevalence of dementia and risk factor profiles may be different among different ethnic groups within the same population. For example, the prevalence of dementia in Aboriginal Australians is three times higher than their non-indigenous counterparts (4); and head injury has been identified as a risk factor that is significantly associated with dementia in Aboriginal Australians (5).

Aotearoa NZ is officially recognised as a bicultural country which includes Māori and non-Māori people. Non-Māori are comprised of NZ Europeans, Asian, Pacific People, Middle Eastern, Latin American and Africans. The Treaty of Waitangi is NZ's constitutional document that places the obligation on the NZ government to be responsive to the health needs of Māori, including those living with dementia, and to ensure equitable health outcomes with non-Māori (6). According to the 2018 NZ census, approximately 70% of the people in the total population self-identified as NZ-Europeans, 17% as Māori, 15% as Asians, 8% as Pacific people and 2% as Middle Eastern/Latin American/African (7). The prevalence of dementia is likely to be different among the major ethnic groups in NZ. For example, the largest ethnic minorities

1  
2  
3 (Māori, Asian and Pacific populations) are increasing at a faster rate than NZ European (2);  
4  
5 and we will expect a higher increase in dementia prevalence in these populations. There is also  
6  
7 some evidence to suggest Māori and Pacific people are diagnosed with dementia at a younger  
8  
9 age than NZ Europeans (8), possibly due to their higher rates of cardiovascular risk factors (9,  
10  
11 10). A previous study found that Asian people living in NZ are more likely to have their  
12  
13 dementia undiagnosed and their true prevalence of dementia might be higher than what is  
14  
15 reported in official reports (11).  
16  
17  
18  
19

20 Accurate estimates of dementia prevalence and associated risk factors in NZ are critical to  
21  
22 measure the full impact of dementia, raise public awareness, reduce stigma, and inform policy  
23  
24 development regarding the implementation of evidence-based prevention, treatment and  
25  
26 support services for people with dementia and their families (12). Culturally appropriate and  
27  
28 responsive services for dementia can only be developed if the true extent of the burden of  
29  
30 dementia is known. There has never been a population-based dementia prevalence study in NZ,  
31  
32 so we propose to test the methods required to conduct a fully representative multi-ethnic  
33  
34 national prevalence study of dementia. The aim of this paper is to describe the study protocol  
35  
36 of a validity study and a feasibility study that will prepare the groundwork for a future fully  
37  
38 powered dementia prevalence study in NZ (Figure 1).  
39  
40  
41  
42  
43

44 In urban areas of NZ, there are many diverse communities in which many different languages  
45  
46 are spoken. In the 2013 NZ Census 64% of Chinese, 37% of Indian, 44% of Tongan, and 35%  
47  
48 of Samoan elders aged 65+ years did not speak English (13). There is an inherent educational  
49  
50 and cultural bias in many cognitive tests that were developed for European cultures. Thus,  
51  
52 commonly used English dementia instruments are not appropriate to apply in those  
53  
54 communities and there is a need to use fully adapted and validated instruments that can produce  
55  
56 accurate and comparable ethnic-specific rates for a NZ dementia prevalence study. Due to the  
57  
58 multi-cultural setting in NZ, we elected to use the 10/66 dementia assessment protocol, which  
59  
60



1  
2  
3 was developed to be culturally and linguistically fair and can be administered by trained lay  
4  
5 interviewers (14). The 10/66 protocol has been demonstrated to have a sensitivity of up to 94%  
6  
7 and a specificity of up to 97% in diagnosing dementia (14). It has been previously translated  
8  
9 and validated in many languages, including Spanish, Portuguese, Mandarin and Cantonese  
10  
11  
12 (14). However, it has never been used in Māori or Pacific populations.  
13  
14

15 The objectives of the validity study are to (i) translate and adapt the 10/66 protocol for use in  
16  
17 research with Māori, Samoan, Tongan, and Fijian-Indian (people of Indian ethnicity born in  
18  
19 Fiji Islands) populations; and (ii) test the diagnostic accuracy of these adapted versions in the  
20  
21 respective ethnic groups.  
22  
23

24 The objective of the feasibility study is to test the logistics and feasibility of using the culturally  
25  
26 adapted versions of the 10/66 protocol as a research tool with NZ European, Māori, Chinese,  
27  
28 Samoan, Tongan, and Fijian-Indian people living in the community. The results of the  
29  
30 feasibility study will inform a future fully powered dementia prevalence study in NZ.  
31  
32  
33

34 The largest minority ethnic groups (Samoan, Tongan, Fijian-Indian, and Chinese) will be  
35  
36 included in the study based on availability of bilingual bicultural researchers and interviewers  
37  
38 from the same ethnic groups.  
39  
40  
41

## 42 ***Methods and analysis***

### 43 ***Phase one - validity study***

#### 44 *Stage 1: Translation and adaptation of the 10/66 dementia assessment protocol.*

45  
46 The 10/66 dementia assessment protocol takes approximately ninety minutes to administer; the  
47  
48 main sections of which are described in Table 1.  
49  
50

51 We will adopt a translation procedure based on the World Health Organization translation  
52  
53 guidelines (30). The procedure entails a four-stage process:  
54  
55  
56  
57  
58  
59  
60

- 1) Forward translation: the English version of the 10/66 will be translated into Te Reo Māori (the Māori language), Samoan, Tongan and Fijian Hindi by professional translators, assisted by a clinician;
- 2) Expert advisory panels for the selected ethnicities will review the first draft of the translation and offer advice and possible solutions for acceptability, conceptual validity and tolerability of the translated instruments;
- 3) A bilingual dementia specialist will quality check and back translate the adapted/translated version;
- 4) Pre-testing in individuals with and without dementia and their families to assess how well the questionnaire will be received, and their feedback used to refine the final version.

We acknowledge the importance of building a research team that represents the ethnic backgrounds of the population groups we are seeking to engage for the study. Māori, Samoan, Tongan and Fijian Hindi researchers will assist in the recruitment of expert translators and members for each expert advisory panel and facilitate the meetings.

#### *Stage 2: Diagnostic accuracy*

We will recruit Māori, Samoan, Tongan and Fijian-Indian participants from the Counties Manukau District Health Board (CMDHB) memory service based at Middlemore Hospital in South Auckland, NZ. People who attend the memory service are referred either from primary care or secondary care services. The clinical criteria to access this service is that a person and/or their family living in the community have a primary concern of subjective and/or objective cognitive decline, irrespective of age.

To assess diagnostic test accuracy, we will compare the results of the 10/66 dementia assessment protocol with the clinical diagnoses. The clinical diagnoses will be made by a

1  
2  
3 multidisciplinary team of dementia specialists at the memory service, guided by standard  
4 clinical criteria, including NINCDS-ADRDA criteria for Alzheimer's disease dementia, (31),  
5 NINCDS-AIREN criteria for vascular dementia (32), criteria for Lewy Body dementia (33),  
6 and Lund criteria for frontotemporal dementias (34). Dementia severity is guided by the  
7 Criteria for Dementia Severity or CDR (35); a CDR of 0.5 indicates mild cognitive impairment,  
8 1 is mild severity, 2 and 3 are moderate and severe severity (35).  
9  
10  
11  
12  
13  
14  
15  
16

### 17 *Cases and controls*

18  
19  
20 Eligible participants in the validity study will be 65 years or older and self-identify as Māori,  
21 Samoan, Tongan or Fijian-Indian. Participants must have had a full dementia assessment at the  
22 CMDHB memory service. The assessment or review must have taken place in the previous six  
23 months to avoid the potential progression of normal controls converting to dementia. By using  
24 convenience sampling, we will attempt to recruit a total of 30 participants with a dementia  
25 diagnosis in each of the four ethnic groups, and 30 age and sex-matched controls (who had a  
26 full specialist assessment and were found not to have dementia). Participants will be excluded  
27 if they suffer from any physical or sensory impairment that compromises their ability to  
28 participate in the interview.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 *Informants*

42  
43  
44 All participants will have a family member or main caregiver (informant) who will complete  
45 the "informant" section of the 10/66 protocol (Table 1). An informant is defined as a person  
46 who knows the main participant well.  
47  
48  
49  
50  
51

### 52 *Blinding*

53  
54  
55 The selection, recruitment, and clinical confirmation of case/control status will be carried out  
56 independent of the 10/66 interviewing process. Interviewers will be blind to the case or control  
57  
58  
59  
60

1  
2  
3 group to which the participant belongs, although blinding may be difficult to maintain in cases  
4  
5 of more severe dementia.  
6  
7

### 8 *Interview training and assessment process*

9

10  
11 Lay interviewers will be recruited via electronic resources (university website, email, blogs) or  
12  
13 through contacts from people/students/health professionals known to the study's investigators.  
14  
15 Interviewers must be bicultural and bilingual, identify with at least one of Māori, Fijian-Indian,  
16  
17 Tongan or Samoan ethnicity, and be able to speak English and the ethnic group language  
18  
19 fluently. We will select between two and six interviewers per ethnic group. The interviewers  
20  
21 will be trained by a team of researchers familiar with the 10/66 assessment protocol. The Lead  
22  
23 Co-investigator for each ethnic group will ensure that specific cultural guidelines are included  
24  
25 in the training process. The training will consist of four sessions of approximately three hours  
26  
27 each. In the first session, the “participant” questionnaires and cognitive tests will be reviewed.  
28  
29 In the second session, the “informant” and “head of household” questionnaires, consent forms  
30  
31 and participant information sheets will be reviewed. During the third session, interviewers will  
32  
33 receive training on specific protocols to handle unexpected situations. For example, if mental  
34  
35 health problems are detected during the interview (e.g. suicidal ideation), the PI will be  
36  
37 immediately contacted by the interviewers and after assessing the situation and with their prior  
38  
39 consent, the participant’s / informant’s GP or the appropriate mental health service will be  
40  
41 contacted to inform them about the issue. In the fourth session answers will be provided to  
42  
43 clarify any questions that the interviewers may have had during the training process, in  
44  
45 particular cultural and language issues.  
46  
47  
48  
49  
50  
51

### 52 *Interviews*

53

54  
55 After obtaining written consent, interviewers will conduct the assessment in a manner that is  
56  
57 culturally appropriate and follows the respective cultural protocols. For example, in Māori  
58  
59  
60

1  
2  
3 whānau (*families*), at the beginning of any hui (*social gathering*) and following the karakia  
4 (*prayer*), a round of mihimihi (*introductions and speeches*) usually occurs. During this time  
5  
6 people may share information about where they come from and significant aspects of their  
7  
8 whakapapa (*genealogy*). The interview is usually finished with another karakia. Similarly for  
9  
10 Pacific families, the importance of taking time to build trust and rapport requires the  
11  
12 incorporation of Samoan and Tongan customs - “fa’aSamoa”/ “anga fakaTonga” and an  
13  
14 inherent understanding of Pacific values such as “Tausi le va”/ “Tauhi le va” (nurturing  
15  
16 relationships) and “fa’aaloalo”/ “faka’apa’apa” (respect), which has specific connotations for  
17  
18 interactions and engagement with the elderly. On completion of the assessment session a koha  
19  
20 (*gift*) of a \$100 NZD voucher will be offered to the person and their family as a gesture of  
21  
22 appreciation for their participation.  
23  
24  
25  
26  
27  
28

29 For participants who are unable to give fully informed consent, we will follow the process  
30  
31 recommended by the NZ’s Code of Health and Disability Services Consumers’ Rights (36).  
32  
33 We will approach the family to discuss whether they believe their family member would want  
34  
35 to participate. If the caregiver agrees we will seek written confirmation that they have been  
36  
37 consulted, and are comfortable with the researcher making the decision as to whether their  
38  
39 relative should participate in the study, and that they believe this would be consistent with their  
40  
41 relative’s wishes. If at any time the participant indicates they do not wish to participate, the  
42  
43 interview will be terminated.  
44  
45  
46  
47

### 48 *Analysis Phase 1*

49  
50  
51 The predictive analytic software version 25 (SPSS, Chicago, IL) will be used for data analysis.  
52  
53 Descriptive frequency distributions and mean values will be used to describe the demographic  
54  
55 summary of each ethnic group. Dementia diagnosis will be made using the 10/66 dementia  
56  
57 diagnostic algorithm, which has been described elsewhere (37), but in brief, the algorithm  
58  
59  
60

1  
2  
3 uses the scores obtained from: 1) the Community Screening Instrument, 2) The verbal fluency  
4 test, 3) the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) word list  
5 memory test, and 4) the scores/diagnoses obtained from the Geriatric Mental State (GMS)  
6 interview. The algorithm is processed in two sequential stages: in stage one the total scores for  
7 each component are calculated and in the second stage the final diagnoses are arranged by a  
8 hierarchically structured imposed algorithm (37). In order to obtain the positive predictive  
9 value, negative predictive value, specificity and sensitivity, the resulting dichotomous variable  
10 derived from the algorithm will be assessed against the gold standard clinical diagnoses of  
11 “dementia case” or “no dementia case”. To compare the subcomponents of the 10/66 protocol  
12 between cases and controls, descriptive analyses of categorical variables will be assessed using  
13 chi-square tests and normally distributed continuous variables with Student’s t-test or one-way  
14 ANOVA. Non-parametric variables will be assessed with Mann-Whitney U test or Kruskal-  
15 Wallis.

### 35 ***Phase two – Feasibility study***

36  
37 Phase two is designed to answer the feasibility questions that arise when we attempt to use the  
38 culturally adapted 10/66 dementia assessment tools in community-dwelling participants living  
39 in selected geographic areas. South Auckland was selected for this purpose due to its ethnic  
40 diversity. The feasibility study will include the following ethnic groups: NZ European, Māori,  
41 Fijian-Indian, Chinese, Tongan and Samoan.

42  
43 The six main feasibility questions to be answered are:

- 44 1) How do we sample to ensure we get adequate community representation from the  
45 included ethnic groups?
- 46 2) How do we prepare a workforce to conduct the fieldwork and develop quality control?
- 47 3) How do we raise the awareness of the study in the community to maximize recruitment?

- 1
- 2
- 3
- 4 4) How do we conduct door-knocking to maximize recruitment?
- 5
- 6 5) How do we retain those we have recruited to remain in the study?
- 7
- 8 6) What is the acceptability of study recruitment and the 10/66 assessment process in
- 9
- 10 different ethnic groups?
- 11
- 12

13 The design of the feasibility study will replicate the design of the full dementia prevalence  
14 study. Potential participants will be identified and recruited using door-knocking in the  
15 selected areas that will allow over sampling of non-European ethnic groups. We will include  
16 aged 65 or over living in private residences in the selected areas, and their caregivers/co-  
17 residents. The exclusion criteria are participants unable to identify a friend or family member  
18 to complete the informant schedule, and people living in care homes and retirement villages  
19 (since their sociodemographic and general health status may differ from those in the  
20 community). The same procedures regarding the interview and interviewer training process  
21 will be used for the feasibility study. All stored data will be de-identified and coded with a  
22 unique participant identifier.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 36 37 *Feasibility issues*

#### 38 39 40 *1) Sampling to ensure adequate community representation from the included ethnic groups*

41  
42 This phase is a cross-sectional survey of selected ethnicities identified by a standard procedure  
43 for a population-based sample. It includes a meshblock sampling frame and door-to-door  
44 knocking to recruit a representative sample in the selected areas (38). Meshblocks are defined  
45 as the smallest geographic unit for which Statistics NZ has demographic information  
46 (approximately 100 people). Using NZ Census demographic information and the expected  
47 rates of dementia by age, we will calculate the probability of finding dementia cases in the  
48 community in adults aged 65 years or older in the CMDHB region of South Auckland. We will  
49 then test our sampling methods by selecting meshblocks with the highest proportions of people  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 aged 65+ for each ethnicity. We aim to recruit 25 participants and informants from each of the  
4  
5 groups, enabling us to test the study procedures and materials in all six ethnic communities.  
6  
7

#### 8 *2) Preparing a workforce to conduct the fieldwork and developing quality control*

9

10  
11 The interviewers will be fully trained as described in phase one of the study. Quality control  
12  
13 processes will be conducted before and throughout the study interviews. Interviewers will  
14  
15 practice interviews with volunteers aged 65 or older, without significant medical or psychiatric  
16  
17 comorbidity. The volunteer interviews will be carried out during the training process and  
18  
19 constructive feedback regarding their approach and the conduct of the interview will be  
20  
21 provided.  
22  
23

24  
25 After the training sessions the first two study interviews will be carried out under the  
26  
27 supervision of one of the trainers and specific feedback regarding the interview process will be  
28  
29 provided at the end of the interview. This will assure that the 10/66 assessment protocol is  
30  
31 correctly administered across all the different ethnic groups and will clarify any questions that  
32  
33 may arise during the interview process.  
34  
35  
36

#### 37 *3) Raising awareness of the study in the community – participants and public involvement*

38  
39

40  
41 Three to four months before starting the sample recruitment we will engage with the selected  
42  
43 communities to co-design a study launch strategy in the communities we hope to reach, using  
44  
45 traditional media, social media and ethnic-specific community activities co-facilitated with  
46  
47 community leaders. We will also send information about the study by post to all potential  
48  
49 households in the chosen locations. Once the community engagement activities are completed,  
50  
51 we will start the recruitment of potential participants.  
52  
53  
54

#### 55 *4) Maximizing recruitment by door-knocking*

56  
57  
58  
59  
60



1  
2  
3 The feasibility study will use a door to door recruitment approach. Door knocking will be  
4  
5 conducted at least once a week for 12 months in the selected areas or until a response has been  
6  
7 recorded for each household. The door-knocking team will be composed of bilingual and  
8  
9 bicultural interviewers (at least one per ethnic group). The initial questionnaire will be  
10  
11 conducted on the doorstep and will last approximately ten minutes. If inclusion criteria are met,  
12  
13 the study will be briefly described to the potential participant and, if agreed, we will ask them  
14  
15 for contact details to send further information about the study. The door knockers will return  
16  
17 to households up to four times to maximise response rates before registering a house as “not  
18  
19 answered”. Regardless of whether or not they agree to participate in the study, all participants  
20  
21 who answer our initial questions will receive a koha/gift (a key ring) as a gesture of appreciation  
22  
23 for their time.  
24  
25  
26  
27  
28

29 Information about the study will be sent by mail to the potential participants who have agreed  
30  
31 to be contacted. They will be given the contact phone details of the Lead Co-investigator for  
32  
33 their ethnic group if they wish to discuss the study further. Approximately one week after  
34  
35 sending these documents, a phone call will be made, with the aim of answering any questions  
36  
37 that the potential participant might have and to make an appointment to carry out the interview.  
38  
39 The call will be made by a bilingual bicultural researcher which will reduce any potentially  
40  
41 coercive power differential, facilitating cultural safety. Interviews will be carried out either at  
42  
43 the participant’s home, University of Auckland facilities or other suitable location of their  
44  
45 choice.  
46  
47  
48  
49

##### 50 *5) Retaining those we have recruited to the study*

51  
52

53 Once the participant/informant agrees to participate in the study, he/she will be contacted to  
54  
55 schedule an appointment. Appointments will be arranged by the ethnic-specific Lead Co-  
56  
57 investigator or by someone trained and designated by them (for example, one of the bilingual  
58  
59  
60

1  
2  
3 interviewers). We will contact the participants either by phone call or face-to-face, depending  
4  
5 on which is most culturally appropriate. The contact will be made in the participant's native  
6  
7 language or in English, depending on the participants' preferences. The interviewer will fully  
8  
9 explain the study to all potential participants (including the head of household and family  
10  
11 member participants) and will discuss any concerns. If they agree to participate, we will seek  
12  
13 informed consent from the participant, the informant, and the household informant. Regular  
14  
15 staff meetings will be held with interviewers to obtain feedback that will inform the adaptation  
16  
17 of study protocols. We will also test our fieldwork protocol that includes verification of  
18  
19 ineligible/refusal cases, contact with families to ask and measure that correct protocol was  
20  
21 followed, quality control of data, and observation of interviews.  
22  
23  
24  
25

#### 26 27 *6) Acceptability of study recruitment and assessment in different ethnic groups*

28  
29 We will ask the participants and their families for feedback about the interview and the specific  
30  
31 cultural approach. We will assess the consent procedures (for example, total time used to fill  
32  
33 the consent form, answer questions about the consent form, difficulties around signing/reading  
34  
35 the consent form); questionnaire administration (total time to finish the interview,  
36  
37 appropriateness of the questions, participants' general opinions about the questionnaire); koha  
38  
39 (gift) management (best way to offer koha to participants and participants' opinions about the  
40  
41 koha). Finally, we will ask interviewers to feedback problems that they encounter and will use  
42  
43 this information to refine our recruitment, training procedures, and fieldwork monitoring in the  
44  
45 full study, and to help decide whether to outsource to a survey firm in the full study.  
46  
47  
48  
49

#### 50 51 *Quantitative data collection and reporting:*

52  
53 Recruitment will be assessed by the number of people screened in the selected meshblocks.  
54  
55 We will register the total number of door-knocked houses, number of door-knocked houses  
56  
57 answered and declined, numbers of people over the age of 65 that agree to be contacted, the  
58  
59  
60

1  
2  
3 houses that agreed to be contacted but subsequently declined (and, if possible, the reasons for  
4 declining) as well as final interview response rate. For those who agree to be contacted, we  
5 will measure the retention rate, decline rate, proportion of baseline participants that agree to be  
6 interviewed and the completeness of collected data.  
7  
8  
9  
10  
11

12 Overall, we will measure the proportion of potential participants (and informants) who were  
13 approached, consented and completed the research protocol and adapted 10/66 interview  
14 schedule as a quantitative measure of acceptability.  
15  
16  
17  
18  
19

20 These measures will enable us to test the effectiveness of the sampling procedure and we will  
21 compare our results to NZ Census data to assess whether we reached a representative sample  
22 of the South Auckland population. The numbers of people with dementia identified in each  
23 ethnic group will inform the sample size and the weighted stratification method which is  
24 usually used to estimate prevalence in underrepresented groups in the population in the fully  
25 powered dementia prevalence study.  
26  
27  
28  
29  
30  
31  
32  
33

34 The data collection and analysis timeline are described in Table 2.  
35  
36

37 *Patient and public Involvement*  
38  
39

## 40 **Discussion**

41  
42

43 There has never been a population-based dementia prevalence study in NZ. Thus, we do not  
44 have a clear idea of the true extent and impact of dementia both overall and, in particular, in  
45 Māori and Pacific people who may be at greater risk yet remain undiagnosed. A dementia  
46 prevalence study that represents all major ethnic groups in NZ is needed to (1) measure the true  
47 extent of dementia in NZ; (2) examine the risk factor profiles in each ethnic group; (3) measure  
48 the care arrangements and caregiver burden in families living with dementia, and (4) determine  
49 the economic impact of dementia on families and on society. The major impact of this study is  
50 the creation of new knowledge about the community prevalence of dementia in NZ, both  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 overall and for all major ethnic groups, which is essential to inform culturally appropriate  
4 strategies to reduce the impact of dementia. The findings from the full study will provide robust  
5 evidence about the numbers of people affected, the possible risk factors, caregiver burden and  
6 the financial impact on families. These NZ-specific data can be used by the NZ Ministry of  
7 Health to develop culturally informed policies to raise public awareness about dementia and  
8 dementia prevention, and to plan services that support families living with dementia in all NZ  
9 communities. The study will also demonstrate the benefits of recruiting a qualified, skilled  
10 research team that is representative of the families participating in the study. Taken together,  
11 this study will determine the essential elements required for conducting dementia research in a  
12 multicultural context in New Zealand.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Ethics and dissemination**

28  
29 The validity study was approved by the Northern A Health and Disability Ethics Committee,  
30 Number: 17NTA234; and the feasibility study was approved by the Northern A Health and  
31 Disability Ethics Committee, Number: 18NTA176. The findings will be disseminated through  
32 peer-reviewed academic journals, national and international conferences and public events.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. World Health Organisation. Dementia: a public health priority. Geneva: World Health Organization; 2012 [Available from: <https://apps.who.int/iris/handle/10665/75263>].
2. Deloitte Report for Alzheimer's New Zealand. Updated Dementia Economic Impact Report 2016. New Zealand 2017 [Available from: <https://www.alzheimers.org.nz/getmedia/79f7fd09-93fe-43b0-a837-771027bb23c0/Economic-Impacts-of-Dementia-2017.pdf>].
3. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer report 2015: the global impact of dementia, an analysis of prevalence, incidence, costs and trends. London UK: Alzheimer's Disease International; 2015 [Available from: <http://www.worldalzreport2015.org/downloads/world-alzheimer-report-2015.pdf>].
4. Li SQ, Guthridge SL, Eswara Aratchige P, Lowe MP, Wang Z, Zhao Y, et al. Dementia prevalence and incidence among the Indigenous and non-Indigenous populations of the Northern Territory. *Med J Aust.* 2014;200(8):465-9.
5. Lo Giudice D, Smith K, Fenner S, Hyde Z, Atkinson D, Skeaf L, et al. Incidence and predictors of cognitive impairment and dementia in Aboriginal Australians: A follow-up study of 5 years. *Alzheimer's Dement.* 2016;12(3):252-61.
6. Dyllal L. Dementia: continuation of health and ethnic inequalities in New Zealand. *N Z Med J.* 2014;127(1389):68-80.
7. Stats New Zealand Tataurangi Aotearoa. Statistics about ethnicity give information by the ethnic groups that people identify with or feel they belong to. Statistics New Zealand; 2018 [Available from: <https://www.stats.govt.nz/topics/ethnicity>].
8. Cullum S, Mullin K, Zeng I, Yates S, Payman V, Fisher M, et al. Do community-dwelling Māori and Pacific peoples present with dementia at a younger age and at a later stage compared with NZ Europeans? *Int J Geriatr Psychiatry.* 2018;33(8):1098-104.
9. Joshy G, Simmons D. Epidemiology of diabetes in New Zealand: revisit to a changing landscape. *N Z Med J.* 2006;119(1235): 1999.
10. Simmons D, Harry T, Gatland B. Prevalence of known diabetes in different ethnic groups in inner urban South Auckland. *N Z Med J.* 1999;112(1094):316-9.
11. Martinez-Ruiz A, Huang Y, Gee S, Jamieson H, Cheung G. Individual risk factors for possible undetected dementia amongst community-dwelling older people in New Zealand. *Dementia (London).* 2020;19(3):750-65.

12. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-734.
13. Winnard D, Lee M, Macleod G. Demographic Profile: 2013 Census, Population of Counties Manukau.: Counties Manukau Health, Auckland; 2015 [Available from: <https://www.countiesmanukau.health.nz/assets/About-CMH/Demographics-and-populations/fl7cdca696/Census-2013-profile-for-residents-of-Counties-Manukau.pdf>].
14. Prince MJ. The 10/66 dementia research group - 10 years on. *Indian J Psychiatry*. 2009;51 Suppl 1(Suppl1):S8-s15.
15. Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGE-CAT. *Psychol Med*. 1986;16(1):89-99.
16. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
17. Diagnostic and statistical manual of mental disorders: DSM-IV: Fourth edition. Washington, DC: American Psychiatric Association, 1994.
18. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC. Community screening interview for dementia (CSI 'D'); performance in five disparate study sites. *Int J Geriatr Psychiatry*. 2000;15(6):521-31.
19. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology*. 1989;39(9):1159-65.
20. Luria AR, Haigh B. The working brain: an introduction to neuropsychology. London; Harmondsworth: Allen Lane; Penguin; 1978.
21. Prince M, Ferri CP, Acosta D, Albanese E, Arizaga R, Dewey M, et al. The protocols for the 10/66 dementia research group population-based research programme. *BMC Public Health*. 2007; 7:165.
22. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaité L, van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory--European Version: development of an instrument for international research. EPSILON Study 5. *European Psychiatric Services: Inputs Linked to Outcome Domains and Needs*. *Br J Psychiatry Suppl*. 2000(39):s28-33.
23. Mari JJ, Williams P. A comparison of the validity of two psychiatric screening questionnaires (GHQ-12 and SRQ-20) in Brazil, using Relative Operating Characteristic (ROC) analysis. *Psychol Med*. 1985;15(3):651-9.

- 1
- 2
- 3
- 4 24. Martin AJ. Assessing the multidimensionality of the 12-item General Health
- 5 Questionnaire. *Psychol Rep.* 1999;84(3 Pt 1):927-35.
- 6
- 7 25. Whitlatch CJ, Zarit SH, von Eye A. Efficacy of interventions with caregivers: a
- 8 reanalysis. *Gerontologist.* 1991;31(1):9-14.
- 9
- 10 26. Zarit SH, Reeve KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of
- 11 feelings of burden. *Gerontologist.* 1980;20(6):649-55.
- 12
- 13 27. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers:
- 14 a longitudinal study. *Gerontologist.* 1986;26(3):260-6.
- 15
- 16 28. Dewey ME, Copeland JR. Diagnosis of dementia from the history and aetiology
- 17 schedule. *Int J Geriatr Psychiatry.* 2001;16(9):912-7.
- 18
- 19 29. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al.
- 20 Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. *J*
- 21 *Neuropsychiatry Clin Neurosci.* 2000;12(2):233-9.
- 22
- 23 30. World Health Organization. Process of translation and adaptation of instruments.
- 24 2020 [Available from: [https://www.who.int/substance\\_abuse/research\\_tools/translation/en/.](https://www.who.int/substance_abuse/research_tools/translation/en/)]
- 25
- 26 31. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al.
- 27 The diagnosis of dementia due to Alzheimer's disease: recommendations from the National
- 28 Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for
- 29 Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):263-9.
- 30
- 31 32. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.
- 32 Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN
- 33 International Workshop. *Neurology.* 1993;43(2):250-60.
- 34
- 35 33. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis
- 36 and management of dementia with Lewy bodies: third report of the DLB Consortium.
- 37 *Neurology.* 2005;65(12):1863-72.
- 38
- 39 34. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and
- 40 Manchester Groups. *J Neurol Neurosurg Psychiatry.* 1994;57(4):416-8.
- 41
- 42 35. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure
- 43 for dementia of the Alzheimer type. *Int Psychogeriatr.* 1997;9 Suppl 1:173-6; discussion 7-8.
- 44
- 45 36. Code of Health and Disability Services Consumers' Rights New Zealand: Health &
- 46 Disability Commissioner / Te Toihau Hauora, Hauatanga; 1994 [Available from:
- 47 [https://www.hdc.org.nz/your-rights/about-the-code/code-of-health-and-disability-services-](https://www.hdc.org.nz/your-rights/about-the-code/code-of-health-and-disability-services-consumers-rights)
- 48 [consumers-rights](https://www.hdc.org.nz/your-rights/about-the-code/code-of-health-and-disability-services-consumers-rights)].
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 37. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M, Dementia Research G.  
4 Dementia diagnosis in developing countries: a cross-cultural validation study. *Lancet*.  
5 2003;361(9361):909-17.  
6  
7

8 38. Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology*. 3rd ed. Philadelphia,  
9 USA: Lippincott Williams & Wilkins; 2008.  
10  
11  
12

### 13 **Authors contributions:**

14  
15 AMR, SC and GC drafted the manuscript and all co-authors critically revised the manuscript.  
16  
17 SC, RK, GC, MD and NK contributed to the study design. SC, CRR, NK, SY, GC contributed  
18 to the study analysis design. All co-authors contributed to the study development.  
19  
20  
21

### 22 **Funding statement**

23  
24 This work was supported by Health Research Council of New Zealand, grant number 18/590;  
25 Brain Research New Zealand Centre of Research Excellence, feasibility study grant number  
26 3715238; and a Counties Manukau District Health Board Tupu fund, grant number 498.  
27  
28  
29

### 30 **Competing interest**

31  
32 No competing interests declared  
33

### 34 **Patient consent for publication**

35  
36 Not required  
37  
38

### 39 **Ethics approval**

40  
41 Both the validity (ref: 17NTA234) and feasibility (ref: 18NTA176) studies were approved by  
42 the New Zealand Northern A Health and Disability Ethics Committee – New Zealand  
43 Government / Ministry of Health.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1.** Sections of the 10/66 dementia assessment protocol

Questionnaire	Section	Instruments used
Participant	Clinical mental state interview	GMS B3 (15) generates hierarchically organized ICD10 (16) and DSM-IV (17) diagnoses including dementia
	Cognitive test battery	CSI-D participant version (18)
		CERAD word list memory test (immediate and delayed recall) (19)
		CERAD verbal fluency test (animal naming) (19)
		Palm-fist-hand test from the Luria battery of frontal lobe tasks (20)
Sociodemographic status	Sociodemographic and risk factors questionnaire (participant version) (21)	
Informant	Informant interview	Brief informant history from the CSI-D (18)
		Client Service Receipt Inventory or CSRI (22)
		Self-reported questionnaire (23,24)
		The Zarit Burden Interview or ZBI (25-27)
		History and Aetiology Schedule (28)
	Neuropsychiatric Inventory Questionnaire or NPI-Q (29)	
Sociodemographic status	Sociodemographic and risk factors questionnaire (proxy version)* (21)	
Household	Head of household questionnaire	Questions about house and family income (21)


Abbreviations - ICD: International Classification of Diseases, DSM: Diagnostic and Statistical Manual of Mental Disorders, GMS: Geriatric Mental State; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CSI-D: Community Screening Interview for Dementia.

\*Proxy version will be used if the main participant is unable to complete the participant version of Sociodemographic and risk factors questionnaire.

**Table 2.** Projected data collection and data analysis timeline by months

Study phases	Tasks	Months
Validity study	Adaptation of 10/66 dementia protocols for specific cultures	1 to 3
	Participant recruitment and interview using culture-specific 10/66 protocols	4 to 7
	Data analysis and report writing	8 to 12
Feasibility study	Door-knocking	8 to 12
	Participant recruitment and interview using culture-specific 10/66 protocols	13 to 20
	Data analysis and report writing	20 to 24

**Figure 1.** Living with Dementia in Aotearoa (LiDiA) feasibility study design.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# BMJ Open

## Living with Dementia in Aotearoa (LiDiA): A cross-sectional feasibility study protocol for a multi-ethnic dementia prevalence study in Aotearoa/New Zealand.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046143.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Mar-2021
Complete List of Authors:	<p>Martinez-Ruiz, Adrian; The University of Auckland, Department of Psychological Medicine; Instituto Nacional de Geriatria, Departamento de Epidemiología Demográfica y Determinantes Sociales</p> <p>Yates, Susan; The University of Auckland, Department of Psychological Medicine</p> <p>Cheung, Gary ; The University of Auckland, Department of Psychological Medicine</p> <p>Dudley, Makarena; The University of Auckland, School of Psychology</p> <p>Krishnamurthi, Rita; Auckland University of Technology, National Institute for Stroke and Applied Neurosciences</p> <p>Fa'alau, Fuafiva ; The University of Auckland, School of Population Health</p> <p>Roberts, Mary; Moana Research, Research Department</p> <p>Taufa, Seini ; Moana Research, Research Department</p> <p>Fa'alili-Fidow, Jacinta; Moana Research, Research Department</p> <p>Rivera-Rodriguez, Claudia; The University of Auckland, Department of Statistics</p> <p>Kautoke, Staverton ; Counties Manukau District Health Board, Department of Mental Health Services for Older People</p> <p>Ma'u, Etuini ; The University of Auckland, Department of Psychological Medicine</p> <p>Kerse, Ngaire; The University of Auckland, School of Population Health</p> <p>Cullum, Sarah; The University of Auckland, Department of Psychological Medicine</p>
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Diagnostics, Public health, Mental health, Epidemiology
Keywords:	Dementia < NEUROLOGY, Old age psychiatry < PSYCHIATRY, GERIATRIC MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Living with Dementia in Aotearoa (LiDiA): A cross-sectional feasibility study protocol**  
4 **for a multi-ethnic dementia prevalence study in Aotearoa/New Zealand.**  
5  
6  
7  
8  
9

10 **Adrian Martinez-Ruiz**<sup>1,2</sup>, MD, Susan Yates<sup>1</sup> PhD, Gary Cheung<sup>1</sup> PhD, Makarena Dudley<sup>3</sup>  
11 PhD, Rita Krishnamurthi<sup>4</sup> PhD, Fuafiva Fa'alau<sup>5</sup> PhD, Mary Roberts<sup>6</sup> MNsg, Seini Taufua<sup>6</sup> PhD,  
12 Jacinta Fa'alili-Fidow<sup>6</sup> PhD, Claudia Rivera Rodriguez PhD<sup>7</sup>, Staverton Kautoke<sup>8</sup> MBChB,  
13 Etuini Ma'u<sup>1</sup> MBChB, Ngaire Kerse<sup>5</sup> PhD, Sarah Cullum<sup>1</sup> MBChB PhD.  
14  
15  
16  
17  
18  
19  
20  
21  
22

- 23 (1) Department of Psychological Medicine, The University of Auckland, Auckland, New  
24 Zealand.  
25  
26  
27 (2) Departamento de Epidemiología Demográfica y Determinantes Sociales, Instituto Nacional  
28 de Geriátría, Ciudad de México, México.  
29  
30 (3) School of Psychology, The University of Auckland, Auckland, New Zealand.  
31  
32 (4) National Institute for Stroke and Applied Neurosciences, Auckland University of  
33 Technology, Auckland, New Zealand.  
34  
35 (5) School of Population Health, The University of Auckland, Auckland, New Zealand.  
36  
37 (6) Research Department, Moana Research, Auckland, New Zealand.  
38  
39 (7) Department of Statistics, The University of Auckland, Auckland, New Zealand.  
40  
41 (8) Department of Mental Health Services for Older People, Counties Manukau District Health  
42 Board, Auckland, New Zealand.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Correspondence to Dr Adrian Martinez-Ruiz; Level 3, Building 507, 22-30 Park Avenue,  
54 Grafton, Auckland, New Zealand 1142; a.martinez@auckland.ac.nz; Telephone:  
55 +64093737599, Fax: +6493737013.  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Aotearoa New Zealand (NZ) is officially recognized as a bicultural country comprised of Māori and non-Māori. Recent estimations have projected a threefold increase in dementia prevalence in NZ by 2050, with the greatest increase in non-NZ Europeans. The NZ government will need to develop policies and plan services to meet the demands of the rapid rise in dementia cases. However, to date there is no national data on dementia prevalence and overseas data are used to estimate the NZ dementia statistics. The overall aim of the Living with Dementia in Aotearoa (LiDiA) study is to prepare the groundwork for a large full-scale NZ dementia prevalence study.

**Methods and analysis:** The study has two phases. In phase one, we will adapt and translate the 10/66 dementia assessment protocol to be administered in Māori, Samoan, Tongan and Fijian-Indian elders. The diagnostic accuracy of the adapted 10/66 protocol will be tested in older people from these ethnic backgrounds who were assessed for dementia at a local memory service. In phase two, we will address the feasibility issues of conducting a population-based prevalence study, by applying the adapted 10/66 protocol in South Auckland and will include NZ European, Māori, Samoan, Tongan, Chinese, and Fijian-Indian participants. The feasibility issues to be explored are: (i) How do we sample to ensure we get accurate community representation? (ii) How do we prepare a workforce to conduct the fieldwork and develop quality control? (iii) How do we raise awareness of the study in the community to maximize recruitment? (iv) How do we conduct door-knocking to maximize recruitment? (v) How do we retain those we have recruited to remain in the study? (vi) What is the acceptability of study recruitment and the 10/66 assessment process in different ethnic groups?

## Ethics and dissemination

The validity and feasibility studies were approved by the New Zealand Northern A Health and Disability Ethics Committee, Number: 17NTA234 and 18NTA176 respectively. The findings will be disseminated through peer-reviewed academic journals, national and international conferences and public events. Data will be available upon reasonable request to the corresponding author.

### ***Strengths and limitations of this study***

- This is the first study, conducted by bilingual and bicultural researchers, to test a methodology aimed to determine the feasibility of conducting a multi-ethnic dementia prevalence study in Aotearoa/New Zealand.
- The study will use strict guidelines to adapt, translate and validate the 10/66 dementia assessment instrument in four of the largest ethnic groups living in Aotearoa/New Zealand.
- The study will use meshblock census data and over sampling to ensure inclusive representation of the non-European ethnic groups included in the study.
- Due to time and funding constraints, we will include only the major New Zealand ethnic groups in this feasibility study.
- We will use door-knocking to ascertain our sample; other sampling methods such as using the electoral roll may be more effective but are unlikely to be accurate in the geographic area we have chosen.



## ***Introduction***

Dementia is a global health priority and its prevalence is increasing in many parts of the world due to their ageing populations (1). Governments across the world are developing policies and planning services to meet the health care and social needs of people with dementia. Aotearoa New Zealand (NZ) needs to do the same but to date there is no prevalence data at a national level to inform the extent and impact of dementia on our population. Although it has been projected that over 60,000 people are currently living with dementia in NZ (at a cost of \$1700 million per annum) and it will increase to 170,000 people by 2050 (2), these statistics are extrapolated from other countries data.

Globally, the prevalence of dementia in people aged 60 years and over is reported to be between 5.6% to 7.6% (3). However, the prevalence of dementia and risk factor profiles may be different among different ethnic groups within the same population. For example, the prevalence of dementia in Aboriginal Australians is three times higher than their non-indigenous counterparts (4); and head injury has been identified as a risk factor that is significantly associated with dementia in Aboriginal Australians (5). Other studies have included multi-ethnic samples (6). For example, a study conducted in Singapore used the 10/66 assessment protocol (7) to calculate the prevalence of dementia among their population (6). It included a sample of 2,565 subjects aged 60 years and over who speak Chinese, Malay, Tamil, or other dialects (Hokkien, Cantonese, and Teochew). The instrument was first translated and adapted into those languages that had not been translated before and subsequently applied. The results showed an overall dementia rate of 10% using the 10/66 diagnostic algorithm (6). Interestingly they also found that the Indian population had a lower probability of having dementia compared to the Chinese-speaking population (6). These results demonstrate how the prevalence and aetiologies may vary in different populations. Therefore, careful assessment of each population is essential to establish both the prevalence of dementia and community-specific risk factors related to it.

1  
2  
3 Aotearoa NZ is officially recognised as a bicultural country which includes Māori and non-  
4  
5 Māori people. Non-Māori are comprised of NZ Europeans, Asian, Pacific People, Middle  
6  
7 Eastern, Latin American and Africans. The Treaty of Waitangi is NZ's constitutional document  
8  
9 that places the obligation on the NZ government to be responsive to the health needs of Māori,  
10  
11 including those living with dementia, and to ensure equitable health outcomes with non-Māori  
12  
13 (8). According to the 2018 NZ census, approximately 70% of the people in the total population  
14  
15 self-identified as NZ-Europeans, 17% as Māori, 15% as Asians, 8% as Pacific people, 2% as  
16  
17 Middle Eastern/Latin American/African and 1% as others (9). However, the 2018 NZ census  
18  
19 also included those who identify with more than one ethnicity; thus, the proportion sum is  
20  
21 higher than 100 percent. Also, in urban areas of NZ, there are many diverse communities in  
22  
23 which a large proportion of the people are not able to speak English as reported in the Counties  
24  
25 Manakau Population Census (10) (Table 1). This might be explained by recent New Zealand  
26  
27 immigration policies in which many older people from these ethnic groups emigrated to NZ  
28  
29 following their adult children in the last 20 years, therefore many have had no need to learn  
30  
31 English prior to immigration. Also, they often live in close-knit communities, speaking their  
32  
33 mother tongue in everyday life and hence usually there is no need to learn English after their  
34  
35 arrival in NZ.  
36  
37  
38  
39  
40  
41

42 **Table 1.** Language indicator for the 2013 Counties Manakau population Census in  
43 people aged 65 years and over.

Ethnic group	% of people who are not able to speak English	% people who are able to speak their own language
Chinese	64	90 <sup>a</sup>
Indian	37	56 <sup>b</sup> – 85 <sup>c</sup>
Samoan	35	97
Tongan	44	92

44  
45  
46  
47  
48  
49  
50  
51  
52 <sup>a</sup> Corresponds to the total of people able to speak a Sinitic language

53 <sup>b</sup> Corresponds to people who are able to speak Hindi.

54 <sup>c</sup> Corresponds to people who are able to speak Indian languages other than Hindi.

55 Totals do not add to hundred percent as people might be included in one or more category,  
56 and not all categories included in the report were described in this table.  
57  
58  
59  
60

1  
2  
3 The prevalence of dementia is likely to be different among the major ethnic groups in NZ. For  
4 example, the largest ethnic minorities (Māori, Asian and Pacific populations) are increasing at  
5 a faster rate than NZ European (2); and we will expect a higher increase in dementia prevalence  
6 in these populations. There is also some evidence to suggest Māori and Pacific people are  
7 diagnosed with dementia at a younger age than NZ Europeans (11), possibly due to their higher  
8 rates of cardiovascular risk factors (12,13). A previous study found that Asian people living in  
9 NZ are more likely to have their dementia undiagnosed and their true prevalence of dementia  
10 might be higher than what is reported in official reports (14).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Accurate estimates of dementia prevalence and associated risk factors in NZ are critical to  
23 measure the full impact of dementia, raise public awareness, reduce stigma, and inform policy  
24 development regarding the implementation of evidence-based prevention, treatment and  
25 support services for people with dementia and their families (15). Culturally appropriate and  
26 responsive services for dementia can only be developed if the true extent of the burden of  
27 dementia is known. There has never been a population-based dementia prevalence study in NZ,  
28 so we propose to test the methods required to conduct a fully representative multi-ethnic  
29 national prevalence study of dementia. The aim of this paper is to describe the study protocol  
30 of a validity study and a feasibility study that will prepare the groundwork for a future fully  
31 powered dementia prevalence study in NZ (Figure 1).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 There is an inherent educational and cultural bias in many cognitive tests that were developed  
47 for European cultures. Thus, commonly used English dementia instruments are not appropriate  
48 to apply in those communities and there is a need to use fully adapted and validated instruments  
49 that can produce accurate and comparable ethnic-specific rates for a NZ dementia prevalence  
50 study. Due to the multi-cultural setting in NZ, we elected to use the 10/66 dementia assessment  
51 protocol, which was developed to be culturally and linguistically fair and can be administered  
52 by trained lay interviewers (16). The 10/66 protocol has been demonstrated to have a  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 sensitivity of up to 94% and a specificity of up to 97% in diagnosing dementia (17). It has  
4  
5 been previously translated and validated in many languages, including Spanish, Portuguese,  
6  
7 Mandarin and Cantonese (17). However, it has never been used in Māori or Pacific  
8  
9 populations.  
10

11  
12  
13 The objectives of the validity study are to (i) translate and adapt the 10/66 protocol for use in  
14  
15 research with Māori, Samoan, Tongan, and Fijian-Indian (people of Indian ethnicity born in  
16  
17 Fiji Islands) populations; and (ii) test the diagnostic accuracy of these adapted versions in the  
18  
19 respective ethnic groups.  
20  
21

22  
23 The objective of the feasibility study is to test the logistics and feasibility of using the culturally  
24  
25 adapted versions of the 10/66 protocol as a research tool with NZ European, Māori, Chinese,  
26  
27 Samoan, Tongan, and Fijian-Indian people living in the community. The results of the  
28  
29 feasibility study will inform a future fully powered dementia prevalence study in NZ.  
30  
31

32  
33 The largest minority ethnic groups (Samoan, Tongan, Fijian-Indian, and Chinese) will be  
34  
35 included in the study based on availability of bilingual bicultural researchers and interviewers  
36  
37 from the same ethnic groups.  
38  
39

## 40 ***Methods and analysis***

### 41 ***Phase one - validity study***

#### 42 ***Stage 1: Translation and adaptation of the 10/66 dementia assessment protocol.***

43  
44  
45  
46  
47  
48  
49 The 10/66 dementia assessment protocol takes approximately ninety minutes to administer; the  
50  
51 main sections of which are described in Table 2.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Sections of the 10/66 dementia assessment protocol

Questionnaire	Section	Instruments used
Participant	Clinical mental state interview	GMS B3 (18) generates hierarchically organized ICD10 (19) and DSM-IV (20) diagnoses including dementia
	Cognitive test battery	CSI-D participant version (21)
		CERAD word list memory test (immediate and delayed recall) (22)
		CERAD verbal fluency test (animal naming) (22)
		Palm-fist-hand test from the Luria battery of frontal lobe tasks (23)
Sociodemographic status	Sociodemographic and risk factors questionnaire (participant version) (7)	
Informant	Informant interview	Brief informant history from the CSI-D (21)
		Client Service Receipt Inventory or CSRI (24)
		Self-reported questionnaire (25, 26)
		The Zarit Burden Interview or ZBI (27-29)
		History and Aetiology Schedule (30)
	Neuropsychiatric Inventory Questionnaire or NPI-Q (31)	
Sociodemographic status	Sociodemographic and risk factors questionnaire (proxy version)* (7)	
Household	Head of household questionnaire	Questions about house and family income (7)

Abbreviations - ICD: International Classification of Diseases, DSM: Diagnostic and Statistical Manual of Mental Disorders, GMS: Geriatric Mental State; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CSI-D: Community Screening Interview for Dementia.

\*Proxy version will be used if the main participant is unable to complete the participant version of Sociodemographic and risk factors questionnaire.

We will adopt a translation procedure based on the World Health Organization translation guidelines (32). The procedure entails a four-stage process:

- 1) Forward translation: the English version of the 10/66 will be translated into Te Reo Māori (the Māori language), Samoan, Tongan and Fijian Hindi by professional translators, assisted by a clinician;
- 2) Expert advisory panels for the selected ethnicities will review the first draft of the translation and offer advice and possible solutions for acceptability, conceptual validity and tolerability of the translated instruments;
- 3) A bilingual dementia specialist will quality check and back translate the adapted/translated version;
- 4) Pre-testing in individuals with and without dementia and their families to assess how well the questionnaire will be received, and their feedback used to refine the final version.

We acknowledge the importance of building a research team that represents the ethnic backgrounds of the population groups we are seeking to engage for the study. Māori, Samoan, Tongan and Fijian Hindi researchers will assist in the recruitment of expert translators and members for each expert advisory panel and facilitate the meetings.

#### *Stage 2: Diagnostic accuracy*

We will recruit Māori, Samoan, Tongan and Fijian-Indian participants from the Counties Manukau District Health Board (CMDHB) memory service based at Middlemore Hospital in South Auckland, NZ. People who attend the memory service are referred either from primary care or secondary care services. The clinical criteria to access this service is that a person and/or their family living in the community have a primary concern of subjective and/or objective cognitive decline, irrespective of age.

1  
2  
3 To assess diagnostic test accuracy, we will compare the results of the 10/66 dementia  
4 assessment protocol with the clinical diagnoses. The clinical diagnoses will be made by a  
5 multidisciplinary team of dementia specialists at the memory service, guided by standard  
6 clinical criteria, including NIA-AA criteria for Alzheimer's disease dementia (33), NINCDS-  
7 AIREN criteria for vascular dementia (34), criteria for Lewy Body dementia (35), and the  
8 clinical criteria for frontotemporal dementias (36). Dementia severity is guided by the Criteria  
9 for Dementia Severity or CDR (37); a CDR of 0.5 indicates mild cognitive impairment, 1 is  
10 mild severity, 2 and 3 are moderate and severe severity (37).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 *Cases and controls*

23  
24  
25 Eligible participants in the validity study will be 65 years or older and self-identify as Māori,  
26 Samoan, Tongan or Fijian-Indian. Participants must have had a full dementia assessment at the  
27 CMDHB memory service. The assessment or review must have taken place in the previous six  
28 months to avoid the potential progression of normal controls converting to dementia. By using  
29 convenience sampling, we will attempt to recruit a total of 30 participants with a dementia  
30 diagnosis in each of the four ethnic groups, and 30 age and sex-matched controls (who had a  
31 full specialist assessment and were found not to have dementia). Participants will be excluded  
32 if they suffer from any physical or sensory impairment that compromises their ability to  
33 participate in the interview.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *Informants*

47  
48  
49 All participants will have a family member or main caregiver (informant) who will complete  
50 the "informant" section of the 10/66 protocol (Table 2). An informant is defined as a person  
51 who knows the main participant well.  
52  
53  
54  
55  
56

### 57 *Blinding*

1  
2  
3 The selection, recruitment, and clinical confirmation of case/control status will be carried out  
4 independent of the 10/66 interviewing process. Interviewers will be blind to the case or control  
5  
6  
7  
8 group to which the participant belongs, although blinding may be difficult to maintain in cases  
9  
10 of more severe dementia.

### 11 12 13 *Interview training and assessment process*

14  
15  
16 Lay interviewers will be recruited via electronic resources (university website, email, blogs) or  
17  
18 through contacts from people/students/health professionals known to the study's investigators.  
19  
20 Interviewers must be bicultural and bilingual, identify with at least one of Māori, Fijian-Indian,  
21  
22 Tongan or Samoan ethnicity, and be able to speak English and the ethnic group language  
23  
24 fluently. We will select between two and six interviewers per ethnic group. The interviewers  
25  
26 will be trained by a team of researchers familiar with the 10/66 assessment protocol. The Lead  
27  
28 Co-investigator for each ethnic group will ensure that specific cultural guidelines are included  
29  
30 in the training process. The training will consist of four sessions of approximately three hours  
31  
32 each. In the first session, the “participant” questionnaires and cognitive tests will be reviewed.  
33  
34 In the second session, the “informant” and “head of household” questionnaires, consent forms  
35  
36 and participant information sheets will be reviewed. During the third session, interviewers will  
37  
38 receive training on specific protocols to handle unexpected situations. For example, if mental  
39  
40 health problems are detected during the interview (e.g. suicidal ideation), the PI will be  
41  
42 immediately contacted by the interviewers and after assessing the situation and with their prior  
43  
44 consent, the participant’s / informant’s GP or the appropriate mental health service will be  
45  
46 contacted to inform them about the issue. In the fourth session answers will be provided to  
47  
48 clarify any questions that the interviewers may have had during the training process, in  
49  
50 particular cultural and language issues.  
51  
52  
53  
54  
55

### 56 57 58 *Interviews*



1  
2  
3 After obtaining written consent, interviewers will conduct the assessment in a manner that is  
4 culturally appropriate and follows the respective cultural protocols. For example, in Māori  
5 whānau (*families*), at the beginning of any hui (*social gathering*) and following the karakia  
6 (*prayer*), a round of mihimihi (*introductions and speeches*) usually occurs. During this time  
7 people may share information about where they come from and significant aspects of their  
8 whakapapa (*genealogy*). The interview is usually finished with another karakia. Similarly for  
9 Pacific families, the importance of taking time to build trust and rapport requires the  
10 incorporation of Samoan and Tongan customs - “fa’aSamoa”/ “anga fakaTonga” and an  
11 inherent understanding of Pacific values such as “Tausi le va”/ “Tauhi le va” (nurturing  
12 relationships) and “fa’aaloalo”/ “faka’apa’apa” (respect), which has specific connotations for  
13 interactions and engagement with the elderly. On completion of the assessment session a koha  
14 (*gift*) of a \$100 NZD voucher will be offered to the person and their family as a gesture of  
15 appreciation for their participation. The GMS (18) will assess if the participant was not  
16 interviewed in their mother language or if the participant was using an unclear dialect or accent.  
17 We presume that some of the participants will be to some extent bilingual, however, this will  
18 depend on the characteristics of their life history and other socio-cultural factors. Since the  
19 interviewers will be bilingual, the participants will be able to decide in which language they  
20 prefer the interview to take place.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 For participants who are unable to give fully informed consent, we will follow the process  
46 recommended by the NZ’s Code of Health and Disability Services Consumers’ Rights (38).  
47 We will approach the family to discuss whether they believe their family member would want  
48 to participate. If the caregiver agrees we will seek written confirmation that they have been  
49 consulted, and are comfortable with the researcher making the decision as to whether their  
50 relative should participate in the study, and that they believe this would be consistent with their  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 relative's wishes. If at any time the participant indicates they do not wish to participate, the  
4  
5 interview will be terminated.  
6  
7

### 8 *Analysis Phase 1*

9  
10  
11 The predictive analytic software version 25 (SPSS, Chicago, IL) will be used for data analysis.  
12  
13 Descriptive frequency distributions and mean values will be used to describe the demographic  
14  
15 summary of each ethnic group. Dementia diagnosis will be made using the 10/66 dementia  
16  
17 diagnostic algorithm, which has been described elsewhere (17), but in brief, the algorithm  
18  
19 uses the scores obtained from: 1) the Community Screening Instrument (21), 2) The verbal  
20  
21 fluency test (22), 3) the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)  
22  
23 word list memory test (22), and 4) the scores/diagnoses obtained from the Geriatric Mental  
24  
25 State (GMS) interview (18). The algorithm is processed in two sequential stages: in stage one  
26  
27 the total scores for each component are calculated and in the second stage the final diagnoses  
28  
29 are arranged by a hierarchically structured imposed algorithm (7, 17). In order to obtain the  
30  
31 positive predictive value, negative predictive value, specificity and sensitivity, the resulting  
32  
33 dichotomous variable derived from the algorithm will be assessed against the gold standard  
34  
35 clinical diagnoses of "dementia case" or "no dementia case". To compare the subcomponents  
36  
37 of the 10/66 protocol between cases and controls, descriptive analyses of categorical variables  
38  
39 will be assessed using chi-square tests and normally distributed continuous variables with  
40  
41 Student's t-test or one-way ANOVA. Non-parametric variables will be assessed with Mann-  
42  
43 Whitney U test or Kruskal-Wallis.  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 *Phase two – Feasibility study*

54  
55 Phase two is designed to answer the feasibility questions that arise when we attempt to use the  
56  
57 culturally adapted 10/66 dementia assessment tools in community-dwelling participants living  
58  
59 in selected geographic areas. South Auckland was selected for this purpose due to its ethnic  
60

1  
2  
3 diversity. The feasibility study will include the following ethnic groups: NZ European, Māori,  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

diversity. The feasibility study will include the following ethnic groups: NZ European, Māori, Fijian-Indian, Chinese, Tongan and Samoan.

The six main feasibility questions to be answered are:

- 1) How do we sample to ensure we get adequate community representation from the included ethnic groups?
- 2) How do we prepare a workforce to conduct the fieldwork and develop quality control?
- 3) How do we raise the awareness of the study in the community to maximize recruitment?
- 4) How do we conduct door-knocking to maximize recruitment?
- 5) How do we retain those we have recruited to remain in the study?
- 6) What is the acceptability of study recruitment and the 10/66 assessment process in different ethnic groups?

The design of the feasibility study will replicate the design of the full dementia prevalence study. Potential participants will be identified and recruited using door-knocking in the selected areas that will allow over sampling of non-European ethnic groups. We will include aged 65 or over living in private residences in the selected areas, and their caregivers/co-residents. The exclusion criteria are participants unable to identify a friend or family member to complete the informant schedule, and people living in long-term care facilities and retirement villages (since their overall dementia prevalence, sociodemographic and general health status may differ from those in the community, and thus it might introduce results bias in our relatively small community sample). The same procedures regarding the interview and interviewer training process will be used for the feasibility study. All stored data will be de-identified and coded with a unique participant identifier.

### *Feasibility issues*

#### *1) Sampling to ensure adequate community representation from the included ethnic groups*

1  
2  
3 This phase is a cross-sectional survey of selected ethnicities identified by a standard procedure  
4 for a population-based sample. It includes a meshblock sampling frame and door-to-door  
5 knocking to recruit a representative sample in the selected areas (39). Meshblocks are defined  
6 as the smallest geographic unit for which Statistics NZ has demographic information  
7 (approximately 100 people). Using NZ Census demographic information and the expected  
8 rates of dementia by age, we will calculate the probability of finding dementia cases in the  
9 community in adults aged 65 years or older in the CMDHB region of South Auckland. We will  
10 then test our sampling methods by selecting meshblocks with the highest proportions of people  
11 aged 65+ for each ethnicity. We aim to recruit 25 participants and informants from each of the  
12 groups, enabling us to test the study procedures and materials in all six ethnic communities.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *2) Preparing a workforce to conduct the fieldwork and developing quality control*

27  
28  
29

30 The interviewers will be fully trained as described in phase one of the study. Quality control  
31 processes will be conducted before and throughout the study interviews. Interviewers will  
32 practice interviews with volunteers aged 65 or older, without significant medical or psychiatric  
33 comorbidity. The volunteer interviews will be carried out during the training process and  
34 constructive feedback regarding their approach and the conduct of the interview will be  
35 provided.  
36  
37  
38  
39  
40  
41  
42  
43

44 After the training sessions the first two study interviews will be carried out under the  
45 supervision of one of the trainers and specific feedback regarding the interview process will be  
46 provided at the end of the interview. This will assure that the 10/66 assessment protocol is  
47 correctly administered across all the different ethnic groups and will clarify any questions that  
48 may arise during the interview process.  
49  
50  
51  
52  
53  
54

### 55 *3) Raising awareness of the study in the community – participants and public involvement*

56  
57  
58  
59  
60

1  
2  
3 Three to four months before starting the sample recruitment we will engage with the selected  
4 communities to co-design a study launch strategy in the communities we hope to reach, using  
5 traditional media, social media and ethnic-specific community activities co-facilitated with  
6 community leaders. We will also send information about the study by post to all potential  
7 households in the chosen locations. Subsequently, we will ask study participants to feedback  
8 if/how they knew about the study beforehand, informing our launch strategy for the full study.  
9  
10 Once the community engagement activities are completed, we will start the recruitment of  
11 potential participants.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

#### 22 *4) Maximizing recruitment by door-knocking*

23  
24 The feasibility study will use a door to door recruitment approach. Door knocking will be  
25 conducted at least once a week for 12 months in the selected areas or until a response has been  
26 recorded for each household. The door-knocking team will be composed of bilingual and  
27 bicultural interviewers (at least one per ethnic group). The initial questionnaire will be  
28 conducted on the doorstep and will last approximately ten minutes. If inclusion criteria are met,  
29 the study will be briefly described to the potential participant and, if agreed, we will ask them  
30 for contact details to send further information about the study. The door knockers will return  
31 to households up to four times to maximise response rates before registering a house as “not  
32 answered”. Regardless of whether or not they agree to participate in the study, all participants  
33 who answer our initial questions will receive a koha/gift (a key ring) as a gesture of appreciation  
34 for their time.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Information about the study will be sent by mail to the potential participants who have agreed  
52 to be contacted. They will be given the contact phone details of the Lead Co-investigator for  
53 their ethnic group if they wish to discuss the study further. Approximately one week after  
54 sending these documents, a phone call will be made, with the aim of answering any questions  
55  
56  
57  
58  
59  
60

1  
2  
3 that the potential participant might have and to make an appointment to carry out the interview.  
4  
5 The call will be made by a bilingual bicultural researcher which will reduce any potentially  
6  
7 coercive power differential, facilitating cultural safety. Interviews will be carried out either at  
8  
9 the participant's home, University of Auckland facilities or other suitable location of their  
10  
11 choice.  
12  
13

#### 14 15 *5) Retaining those we have recruited to the study*

16  
17  
18 Once the participant/informant agrees to participate in the study, he/she will be contacted to  
19  
20 schedule an appointment. Appointments will be arranged by the ethnic-specific Lead Co-  
21  
22 investigator or by someone trained and designated by them (for example, one of the bilingual  
23  
24 interviewers). We will contact the participants either by phone call or face-to-face, depending  
25  
26 on which is most culturally appropriate. The contact will be made in the participant's native  
27  
28 language or in English, depending on the participants' preferences. The interviewer will fully  
29  
30 explain the study to all potential participants (including the head of household and family  
31  
32 member participants) and will discuss any concerns. If they agree to participate, we will seek  
33  
34 informed consent from the participant, the informant, and the household informant. Regular  
35  
36 staff meetings will be held with interviewers to obtain feedback that will inform the adaptation  
37  
38 of study protocols. We will also test our fieldwork protocol that includes verification of  
39  
40 ineligible/refusal cases, contact with families to ask and measure that correct protocol was  
41  
42 followed, quality control of data, and observation of interviews.  
43  
44  
45  
46  
47

#### 48 49 *6) Acceptability of study recruitment and assessment in different ethnic groups*

50  
51 We will ask the participants and their families for feedback about the interview and the specific  
52  
53 cultural approach. We will assess the consent procedures (for example, total time used to fill  
54  
55 the consent form, answer questions about the consent form, difficulties around signing/reading  
56  
57 the consent form); questionnaire administration (total time to finish the interview,  
58  
59  
60

1  
2  
3 appropriateness of the questions, participants' general opinions about the questionnaire); koha  
4  
5 (gift) management (best way to offer koha to participants and participants' opinions about the  
6  
7 koha). Finally, we will ask interviewers to feedback problems that they encounter and will use  
8  
9 this information to refine our recruitment, training procedures, and fieldwork monitoring in the  
10  
11 full study, and to help decide whether to outsource to a survey firm in the full study.  
12  
13

14  
15 *Quantitative data collection and reporting:*  
16

17  
18 Recruitment will be assessed by the number of people screened in the selected meshblocks.  
19  
20 We will register the total number of door-knocked houses, number of door-knocked houses  
21  
22 answered and declined, numbers of people over the age of 65 that agree to be contacted, the  
23  
24 houses that agreed to be contacted but subsequently declined (and, if possible, the reasons for  
25  
26 declining) as well as final interview response rate. For those who agree to be contacted, we  
27  
28 will measure the retention rate, decline rate, proportion of baseline participants that agree to be  
29  
30 interviewed and the completeness of collected data.  
31  
32

33  
34 Overall, we will measure the proportion of potential participants (and informants) who were  
35  
36 approached, consented and completed the research protocol and adapted 10/66 interview  
37  
38 schedule as a quantitative measure of acceptability.  
39  
40

41  
42 These measures will enable us to test the effectiveness of the sampling procedure and we will  
43  
44 compare our results to NZ Census data to assess whether we reached a representative sample  
45  
46 of the South Auckland population. The numbers of people with dementia identified in each  
47  
48 ethnic group will inform the sample size and the weighted stratification method which is  
49  
50 usually used to estimate prevalence in underrepresented groups in the population in the fully  
51  
52 powered dementia prevalence study.  
53  
54

55  
56 The data collection and analysis timeline are described in Table 3.  
57  
58  
59  
60

**Table 3.** Projected data collection and data analysis timeline by months

Study phases	Tasks	Months
Validity study	Adaptation of 10/66 dementia protocols for specific cultures	1 to 3
	Participant recruitment and interview using culture-specific 10/66 protocols	4 to 7
	Data analysis and report writing	8 to 12
Feasibility study	Door-knocking	8 to 12
	Participant recruitment and interview using culture-specific 10/66 protocols	13 to 20
	Data analysis and report writing	20 to 24

### *Patient and public involvement*

Before starting the study, we will engage with the selected communities to conduct educational sessions and also conduct qualitative research to identify the main concerns about dementia in each ethnic group. Other sessions have already been conducted through local non-governmental organisations serving older people in different ethnic groups living in New Zealand, plus cross-cultural interest groups with Asian health professionals regarding the best ways to conduct dementia research in their communities (40). We will also invite members from the different communities to a study launch.

### **Discussion**

There has never been a population-based dementia prevalence study in NZ. Thus, we do not have a clear idea of the true extent and impact of dementia both overall and, in particular, in Māori and Pacific people who may be at greater risk yet remain undiagnosed. A dementia prevalence study that represents all major ethnic groups in NZ is needed to (1) measure the true extent of dementia in NZ; (2) examine the risk factor profiles in each ethnic group; (3) measure the care arrangements and caregiver burden in families living with dementia, and (4) determine the economic impact of dementia on families and on society. The major impact of this study is the creation of new knowledge about the community prevalence of dementia in NZ, both



1  
2  
3 overall and for all major ethnic groups, which is essential to inform culturally appropriate  
4 strategies to reduce the impact of dementia.  
5  
6

7  
8 There are some limitations that need to be acknowledged: (i) the sampling methodology was  
9 based on convenience sampling. Although sample sizes between 24 and 50 have been  
10 recommended for pilot studies (41-43) and convenience sampling may provide accurate  
11 correlations and rich qualitative information, it will not offer generalisable results to the overall  
12 NZ population. However, this study will lay the foundations for a future national prevalence  
13 study representing all the ethnic groups included in our research. (ii) Not all ethnic minorities  
14 in New Zealand will be included in this phase of the study; other ethnic groups will need to be  
15 included in future studies, for example, people from other Pacific Islands, Middle Easterners,  
16 Latin American, and Africans. (iii) Another limitation is that we will only include people aged  
17 65 years or over. Future studies, including people with younger onset dementia, particularly  
18 from the ethnic groups that have shown to be at a higher risk of developing dementia at a  
19 younger age (such as Maori and Pacific People), will be needed to clarify this issue (iv) The  
20 feasibility phase will only include people recruited from the community. Consequently, people  
21 living in long-term care facilities and retirement villages will be excluded from our study.  
22 However, we intend to conduct a future study using the Long-Term Care Facility version of  
23 the International Residential Assessment Instrument (interRAI) (44). interRAI routinely  
24 collects information on dementia diagnosis and is mandated by the Ministry of Health to be  
25 completed with every long-term care facility residents every 6 months. We also have planned  
26 to conduct a dementia prevalence study in long-term care facilities using the 10/66 instruments  
27 (reference standard) and compare the results against interRAI data to assess their utility for  
28 ongoing dementia surveillance. (v) Finally, our study will be carried out in a multi-ethnic urban  
29 area. Nevertheless, in less ethnically diverse regions, it may be more challenging to recruit  
30 bilingual interviewers for ethnic minorities other than Maori. It would mean looking for  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 alternatives to recruit interviewers for these populations—for example, mobilizing bilingual  
4 interviewers from one location to another, which will increase the study costs but present more  
5 accurate results. Additionally, in rural areas is likely that different engaging strategies will have  
6 to be sought. For example, disseminating the study in a rural population might require other  
7 engaging methods (such as face-to-face) compared to the methods used in urban areas. Also,  
8 due to cultural factors, the participation and declining rates might be different from less to more  
9 ethnically diverse areas and from rural to urban areas. A specific engaging method will have  
10 tested for these areas.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 The findings from the full prevalence study will provide robust evidence about the numbers of  
23 people affected, the possible risk factors, caregiver burden and the financial impact on families.  
24 These NZ-specific data can be used by the NZ Ministry of Health to develop culturally  
25 informed policies to raise public awareness about dementia and dementia prevention, and to  
26 plan services that support families living with dementia in all NZ communities. The study will  
27 also demonstrate the benefits of recruiting a qualified, skilled research team that is  
28 representative of the families participating in the study. Taken together, this study will  
29 determine the essential elements required for conducting dementia research in a multicultural  
30 context in New Zealand.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Ethics and dissemination**

44 The validity study was approved by the Northern A Health and Disability Ethics Committee,  
45 Number: 17NTA234; and the feasibility study was approved by the Northern A Health and  
46 Disability Ethics Committee, Number: 18NTA176. The findings will be disseminated through  
47 peer-reviewed academic journals, national and international conferences and public events.  
48  
49  
50  
51  
52

### 53 **Authors contributions:**

54 AMR, SC and GC drafted the manuscript and all co-authors critically revised the manuscript.  
55  
56  
57 SC, RK, GC, MD and NK contributed to the study design. SC, CRR, NK, SY, GC contributed  
58  
59  
60

1  
2  
3 to the study analysis design. AMR, SC, GC, MD, RK, FF, MR, ST, JFF, CRR, SK, EM, NK,  
4  
5 and SC contributed to the study development.  
6  
7

### 8 **Funding statement**

9  
10 This work was supported by Health Research Council of New Zealand, grant number 18/590;  
11  
12 Brain Research New Zealand Centre of Research Excellence, feasibility study grant number  
13  
14 3715238; and a Counties Manukau District Health Board Tupu fund, grant number 498.  
15  
16

### 17 **Competing interest**

18  
19 No competing interests declared  
20  
21

### 22 **Patient consent for publication**

23  
24 Not required  
25  
26

### 27 **Ethics approval**

28  
29 Both the validity (ref: 17NTA234) and feasibility (ref: 18NTA176) studies were approved by  
30  
31 the New Zealand Northern A Health and Disability Ethics Committee – New Zealand  
32  
33 Government / Ministry of Health.  
34  
35

### 36 **References**

- 37  
38 1. World Health Organisation. Dementia: a public health priority. Geneva: World Health  
39  
40 Organization; 2012 [Available from: <https://apps.who.int/iris/handle/10665/75263>].  
41  
42 2. Deloitte Report for Alzheimer's New Zealand. Updated Dementia Economic Impact  
43  
44 Report 2016. New Zealand 2017 [Available from:  
45  
46 [https://www.alzheimers.org.nz/getmedia/79f7fd09-93fe-43b0-a837-  
47  
48 771027bb23c0/Economic-Impacts-of-Dementia-2017.pdf/](https://www.alzheimers.org.nz/getmedia/79f7fd09-93fe-43b0-a837-771027bb23c0/Economic-Impacts-of-Dementia-2017.pdf/)].  
49  
50 3. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer report 2015:  
51  
52 the global impact of dementia, an analysis of prevalence, incidence, costs and trends. . London  
53  
54 UK: Alzheimer's Disease International; 2015.  
55  
56 4. Li SQ, Guthridge SL, Eswara Aratchige P, Lowe MP, Wang Z, Zhao Y, et al. Dementia  
57  
58 prevalence and incidence among the Indigenous and non-Indigenous populations of the  
59  
60 Northern Territory. Med J Aust. 2014;200(8):465-9.

- 1  
2  
3 5. Lo Giudice D, Smith K, Fenner S, Hyde Z, Atkinson D, Skeaf L, et al. Incidence and  
4 predictors of cognitive impairment and dementia in Aboriginal Australians: A follow-up study  
5 of 5 years. *Alzheimers Dement*. 2016;12(3):252-61.  
6  
7
- 8 6. Subramaniam M, Chong SA, Vaingankar JA, Abdin E, Chua BY, Chua HC, et al.  
9 Prevalence of Dementia in People Aged 60 Years and Above: Results from the WiSE Study. *J*  
10 *Alzheimers Dis*. 2015;45(4):1127-38.  
11  
12
- 13 7. Prince M, Ferri CP, Acosta D, Albanese E, Arizaga R, Dewey M, et al. The protocols  
14 for the 10/66 dementia research group population-based research programme. *BMC Public*  
15 *Health*. 2007;7:165.  
16  
17
- 18 8. Dyllal L. Dementia: continuation of health and ethnic inequalities in New Zealand. *N Z*  
19 *Med J*. 2014;127(1389):68-80.  
20  
21
- 22 9. Stats New Zealand Tatauranga Aotearoa. Statistics about ethnicity give information by  
23 the ethnic groups that people identify with or feel they belong to. Statistics New Zealand; 2018  
24 [Available from: <https://www.stats.govt.nz/topics/ethnicity>].  
25  
26
- 27 10. Winnard D, Lee M, Macleod G. Demographic Profile: 2013 Census, Population of  
28 Counties Manukau.: Counties Manakau Health; 2015.  
29  
30
- 31 11. Cullum S, Mullin K, Zeng I, Yates S, Payman V, Fisher M, et al. Do community-  
32 dwelling Māori and Pacific peoples present with dementia at a younger age and at a later stage  
33 compared with NZ Europeans? *Int J Geriatr Psychiatry*. 2018;33(8):1098-104.  
34  
35
- 36 12. Joshy G, Simmons D. Epidemiology of diabetes in New Zealand: revisit to a changing  
37 landscape. *N Z Med J*. 2006;119(1235):U1999.  
38  
39
- 40 13. Simmons D, Harry T, Gatland B. Prevalence of known diabetes in different ethnic  
41 groups in inner urban South Auckland. *N Z Med J*. 1999;112(1094):316-9.  
42  
43
- 44 14. Martinez-Ruiz A, Huang Y, Gee S, Jamieson H, Cheung G. Individual risk factors for  
45 possible undetected dementia amongst community-dwelling older people in New Zealand.  
46 *Dementia (London)*. 2020;19(3):750-65.  
47  
48
- 49 15. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al.  
50 Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-734.  
51  
52
- 53 16. Prince MJ. The 10/66 dementia research group - 10 years on. *Indian J Psychiatry*.  
54 2009;51 Suppl 1(Suppl1):S8-s15.  
55  
56
- 57 17. Prince M, Acosta D, Chiu H, Sczufca M, Varghese M, Dementia Research G.  
58 Dementia diagnosis in developing countries: a cross-cultural validation study. *Lancet*.  
59 2003;361(9361):909-17.  
60


18. Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGE-CAT. *Psychol Med.* 1986;16(1):89-99.
19. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
20. Diagnostic and statistical manual of mental disorders: DSM-IV: Fourth edition. Washington, DC: American Psychiatric Association, 1994.
21. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC. Community screening interview for dementia (CSI 'D'); performance in five disparate study sites. *Int J Geriatr Psychiatry.* 2000;15(6):521-31.
22. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology.* 1989;39(9):1159-65.
23. Luria AR, Haigh B. *The working brain : an introduction to neuropsychology.* [London]; Harmondsworth: Allen Lane; Penguin; 1978.
24. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaité L, van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory--European Version: development of an instrument for international research. EPSILON Study 5. *European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br J Psychiatry Suppl.* 2000(39):s28-33.
25. Martin AJ. Assessing the multidimensionality of the 12-item General Health Questionnaire. *Psychol Rep.* 1999;84(3 Pt 1):927-35.
26. Mari JJ, Williams P. A comparison of the validity of two psychiatric screening questionnaires (GHQ-12 and SRQ-20) in Brazil, using Relative Operating Characteristic (ROC) analysis. *Psychol Med.* 1985;15(3):651-9.
27. Whitlatch CJ, Zarit SH, von Eye A. Efficacy of interventions with caregivers: a reanalysis. *Gerontologist.* 1991;31(1):9-14.
28. Zarit SH, Reeve KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. *Gerontologist.* 1980;20(6):649-55.
29. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. *Gerontologist.* 1986;26(3):260-6.
30. Dewey ME, Copeland JR. Diagnosis of dementia from the history and aetiology schedule. *Int J Geriatr Psychiatry.* 2001;16(9):912-7.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
31. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. *J Neuropsychiatry Clin Neurosci*. 2000;12(2):233-9.
  32. World Health Organization. Process of translation and adaptation of instruments. 2020 [Available from: [https://www.who.int/substance\\_abuse/research\\_tools/translation/en/](https://www.who.int/substance_abuse/research_tools/translation/en/).]
  33. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-62.
  34. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology*. 1993;43(2):250-60.
  35. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88-100.
  36. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology*. 1998;51(6):1546-54.
  37. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr*. 1997;9 Suppl 1:173-6; discussion 7-8.
  38. Code of Health and Disability Services Consumers' Rights New Zealand: Health & Disability Commissioner / Te Toihau Hauora, Hauatanga; 1994 [Available from: <https://www.hdc.org.nz/your-rights/about-the-code/code-of-health-and-disability-services-consumers-rights>].
  39. Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology*. 3rd Ed ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008.
  40. Cheung G, Appleton K, Boyd M, Cullum S. Perspectives of dementia from Asian communities living in New Zealand: A focus group of Asian health care professionals. *Int J Geriatr Psychiatry*. 2019;34(12):1758-64.
  41. Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. *J Clin Epidemiol*. 2012;65(3):301-8.
  42. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceutical Statistics*. 2005;4(4):287-91.
  43. Browne RH. On the use of a pilot sample for sample size determination. *Stat Med*. 1995;14(17):1933-40.

1  
2  
3 44. Hirdes JP, Ljunggren G, Morris JN, Frijters DHM, Finne Soveri H, Gray L, et al.  
4 Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated  
5 health information system. BMC Health Services Research. 2008;8(1):277.  
6  
7  
8  
9

10  
11 **Figure 1.** Living with Dementia in Aotearoa (LiDiA) feasibility study design.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46